POST LEONARD E sold $75K of CGON
POST LEONARD E sold 1,000 shares of CG Oncology, Inc. (CGON) at $74.54 on 2026-08-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price, and that it was executed under a 10b5-1 plan, which typically reduces interpretive weight.
Market read
This is a routine insider sale disclosure with limited trading edge unless paired with other company-specific catalysts.
What to watch
Because the sale is explicitly under a pre-arranged 10b5-1 plan and the size is modest, the informational content is likely limited versus operational or clinical updates.
Background
The article is a SEC Form 4 insider transaction disclosure for CG Oncology, Inc., reported by director Leonard E Post.
Ticker impact
CG Oncology director Leonard E Post sold 1,000 shares in an open-market transaction at $74.54 on 2026-08-14 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale; any impact would be short-lived.
The filing is a small, pre-arranged 10b5-1 sale by a director, with no accompanying fundamental catalyst or guidance change disclosed in the text.
Market effects
No sector-level implications are disclosed; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Traders sometimes treat insider sales as bearish even when 10b5-1, so there could be a brief sentiment dip if liquidity is thin.
Key entities
- issuerCG Oncology, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderLeonard E Post
Director who sold 1,000 shares in an open-market transaction under a 10b5-1 plan.